The present invention relates to a novel crystal form of acalabrutinib, a preparation method thereof, a pharmaceutical composition comprising the crystal form, and a use of the crystal form in preparing a Bruton's tyrosine kinase inhibitor or a pharmaceutical preparation for treating mantle cell lymphoma. The crystal form of acalabrutinib provided by the present invention has one or more improved properties compared to the prior art and is of great value for the optimization and development of the drug in the future.
